Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
NoMoreC in Amsterdam: gedurfde HCV-aanpak werpt vruchten af
nov 2019 | Hepatitis